Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 9
1996 20
1997 9
1998 14
1999 14
2000 24
2001 25
2002 31
2003 33
2004 46
2005 49
2006 65
2007 68
2008 49
2009 51
2010 51
2011 70
2012 60
2013 40
2014 39
2015 31
2016 44
2017 39
2018 49
2019 32
2020 27
Text availability
Article attribute
Article type
Publication date

Search Results

911 results
Results by year
Filters applied: . Clear all
Page 1
Classics in Chemical Neuroscience: Risperidone.
Chopko TC, Lindsley CW. Chopko TC, et al. ACS Chem Neurosci. 2018 Jul 18;9(7):1520-1529. doi: 10.1021/acschemneuro.8b00159. Epub 2018 May 11. ACS Chem Neurosci. 2018. PMID: 29695153 Review.
Despite initial Food and Drug Administration approval 25 years ago, risperidone continues to be a fundamental treatment for schizophrenia, bipolar I disorder, and autism-related irritability. It is on the World Health Organization's List of Essential Medicine …
Despite initial Food and Drug Administration approval 25 years ago, risperidone continues to be a fundamental treatment for schizophr …
Risperidone for bipolar disorders.
Sajatovic M, Madhusoodanan S, Fuller MA, Aulakh L, Keaton DB. Sajatovic M, et al. Expert Rev Neurother. 2005 Mar;5(2):177-87. doi: 10.1586/14737175.5.2.177. Expert Rev Neurother. 2005. PMID: 15853488 Review.
A number of controlled and open-label treatment trials have shown risperidone's efficacy and tolerability in the manic phase of bipolar disorder. Risperidone has also been reported to be useful in the longer-term treatment of bipolar disorder. T …
A number of controlled and open-label treatment trials have shown risperidone's efficacy and tolerability in the manic phase o …
Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis.
Valdes M, Bertolin S, Qian H, Wong H, Lam RW, Yatham LN. Valdes M, et al. J Affect Disord. 2019 Mar 1;246:861-866. doi: 10.1016/j.jad.2019.01.003. Epub 2019 Jan 5. J Affect Disord. 2019. PMID: 30795492 Clinical Trial.
BACKGROUND: Risperidone, an atypical antipsychotic medication, is recommended as a first line treatment for acute mania in patients with bipolar disorder I (BD I). ...METHODS: A post-hoc subgroup analysis was conducted using data from a 52-week, double-blind, placeb …
BACKGROUND: Risperidone, an atypical antipsychotic medication, is recommended as a first line treatment for acute mania in patients w …
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Taylor DM, Cornelius V, Smith L, Young AH. Taylor DM, et al. Acta Psychiatr Scand. 2014 Dec;130(6):452-69. doi: 10.1111/acps.12343. Epub 2014 Oct 6. Acta Psychiatr Scand. 2014. PMID: 25283309 Review.
METHOD: We performed a multiple-treatments meta-analysis of randomised, double-blind, controlled comparisons of 4-16 weeks in adults in bipolar depression. ...Several treatments [monoamine oxidase inhibitors (MAOIs), ziprasidone, aripiprazole and risperidone] have l …
METHOD: We performed a multiple-treatments meta-analysis of randomised, double-blind, controlled comparisons of 4-16 weeks in adults in b
Risperidone treatment of bipolar mania.
Nguyen LN, Guthrie SK. Nguyen LN, et al. Ann Pharmacother. 2006 Apr;40(4):674-82. doi: 10.1345/aph.1G378. Epub 2006 Mar 28. Ann Pharmacother. 2006. PMID: 16569811 Review.
OBJECTIVE: To review clinical trial evidence regarding the efficacy and safety of risperidone for the treatment of bipolar mania. ...STUDY SELECTION AND DATA EXTRACTION: Six randomized trials and 6 observational studies of risperidone monotherapy or combinati …
OBJECTIVE: To review clinical trial evidence regarding the efficacy and safety of risperidone for the treatment of bipolar man …
Risperidone: a review of its use in the treatment of bipolar mania.
Fenton C, Scott LJ. Fenton C, et al. CNS Drugs. 2005;19(5):429-44. doi: 10.2165/00023210-200519050-00005. CNS Drugs. 2005. PMID: 15907153 Review.
Risperidone is now approved in the UK and the US for use in bipolar mania. Risperidone < or =6 mg/day, as monotherapy or adjunctive therapy with first-line mood stabilisers, significantly improves moderate and severe bipolar mania and improves globa
Risperidone is now approved in the UK and the US for use in bipolar mania. Risperidone < or =6 mg/day, as monotherap
A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents.
Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, Axelson DA, Bolhofner K, Robb A, Wolf DV, Riddle MA, Birmaher B, Nusrat N, Ryan ND, Vitiello B, Tillman R, Lavori P. Geller B, et al. Arch Gen Psychiatry. 2012 May;69(5):515-28. doi: 10.1001/archgenpsychiatry.2011.1508. Epub 2012 Jan 2. Arch Gen Psychiatry. 2012. PMID: 22213771 Free PMC article. Clinical Trial.
CONTEXT: There was a paucity of comparative pharmacological research for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. ...MAIN OUTCOME MEASURES: Primary outcome measures were the Clinical Global Impressions for Bipolar I …
CONTEXT: There was a paucity of comparative pharmacological research for initial treatment of bipolar I disorder, manic or mixed phas …
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Temmingh HS, Williams T, Siegfried N, Stein DJ. Temmingh HS, et al. Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011057. doi: 10.1002/14651858.CD011057.pub2. Cochrane Database Syst Rev. 2018. PMID: 29355909 Free PMC article. Review.
BACKGROUND: Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). ...SEARCH METHODS: On 6 January 2016 and 9 October 2017, we searched the Cochrane Schizophrenia Group' …
BACKGROUND: Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substa …
Risperidone long-acting injection: in bipolar I disorder.
Deeks ED. Deeks ED. Drugs. 2010 May 28;70(8):1001-12. doi: 10.2165/11204480-000000000-00000. Drugs. 2010. PMID: 20481656 Review.
A long-acting intramuscular formulation of the atypical antipsychotic agent risperidone is now indicated for the maintenance treatment of patients with bipolar I disorder. ...Maintenance treatment with risperidone long-acting injection, as monotherapy in adul …
A long-acting intramuscular formulation of the atypical antipsychotic agent risperidone is now indicated for the maintenance treatmen …
Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial.
Moosavi SM, Ahmadi M, Monajemi MB. Moosavi SM, et al. Glob J Health Sci. 2014 Jul 29;6(6):163-7. doi: 10.5539/gjhs.v6n6p163. Glob J Health Sci. 2014. PMID: 25363101 Free PMC article. Clinical Trial.
OBJECTIVE: This study compared the efficacy of risperidone monotherapy with risperidone plus valproate in bipolar I disorder, manic phase. ...CONCLUSIONS: Risperidone can be effective and well tolerated in both acute manic episodes of bipolar mo …
OBJECTIVE: This study compared the efficacy of risperidone monotherapy with risperidone plus valproate in bipolar I dis …
911 results
Jump to page
Feedback